1. Show article details.

    Top Gainers Technical Data -- Research on BioScrip, E-House China Holdings, MagneGas, and Idera Pharma

    PR Newswire – 8:47 AM ET 04/09/2014

    LONDON, April 9, 2014 On Tuesday, April 08, 2014, the US markets saw a positive sentiment, with the NASDAQ Composite closing at 4,112.99, up 0.81%, the Dow Jones Industrial Average ending the session at 16,256.14, up 0.06%, and the S&P 500 edging 0.38% higher to finish the trading session at 1,851.96. The session saw a positive impact from Consumer Discretionary, Energy and Utilities sectors al...

  2. Show article details.

    Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic MYD88 L265P Mutation

    Business Wire – 4:05 PM ET 04/07/2014

    Idera Pharmaceuticals, Inc. (IDRA) today presented new preclinical data demonstrating the ability of its Toll-like receptor antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation.

  3. Show article details.

    Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera

    PR Newswire – 8:00 AM ET 04/04/2014

    NEW YORK, April 4, 2014 Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (ARWR), Providence Service Corp. (PRSC), Durata Therapeutics, Inc. (DRTX), Orthofix International N.V. (OFIX), and Idera Pharmaceuticals, Inc. (IDRA). Private wealth members receive these notes ahead of publication.

  4. Show article details.

    Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400

    Business Wire – 7:15 AM ET 03/28/2014

    Idera Pharmaceuticals, Inc. (IDRA) today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. “Successful completion of this trial is an important additional milestone in our TLR antagonist program.

  5. Show article details.

    New Highs & Stocks to Watch -- Research on Penn Virginia, Idera Pharma, US Geothermal, and First Republic Bank

    PR Newswire – 8:23 AM ET 03/19/2014

    LONDON, March 19, 2014 On Tuesday, March 18, 2014, the NASDAQ Composite finished at 4,333.31, up 1.25%. The Dow Jones Industrial Average closed the session at 16,336.19, up 0.55% and the S&P 500 ended the day at 1,872.25, higher by 0.72%. The gains were broad based with 9 of 10 sectors ending the session in positive. SOURCE Investor-Edge.

  6. Show article details.

    Idera Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results and Provides Corporate Update

    Business Wire – 7:50 AM ET 03/13/2014

    Idera Pharmaceuticals, Inc. (IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, today reported its financial and operational results for the fourth quarter and year ended December 31, 2013.

  7. Show article details.

    Idera Pharmaceuticals Announces Expansion of Pipeline into Two Orphan Autoimmune Diseases

    Business Wire – 7:35 AM ET 03/13/2014

    Idera Pharmaceuticals, Inc. (IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune disorders and genetically defined forms of B-cell lymphoma, today announced that it plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan auto...

  8. Show article details.

    Idera Pharmaceuticals Announces Appointment of Julian Baker and Dr. Kelvin Neu to its Board of Directors

    Business Wire – 8:30 AM ET 03/12/2014

    Idera Pharmaceuticals, Inc. (IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Baker Brothers Investments’ Julian C. Baker and Kelvin M. Neu, M.D., joined its Board of Directors, effective March 10, 2014.

  9. Show article details.

    Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014

    Business Wire – 8:30 AM ET 03/06/2014

    Idera Pharmaceuticals, Inc. (IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that the Company will host a conference call and live audio webcast at 8:30 a.m. EDT on Thursday, March 13, 2014 to report its fourth quarter and full year 2013 financial results...

  10. Show article details.

    Idera to Present at the Cowen & Co. 34th Annual Health Care Conference

    Business Wire – 8:30 AM ET 02/26/2014

    Idera Pharmaceuticals, Inc. (IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the Cowen & Co. 34th Annual Health Care Conference on Wednesday, March 5, 2014 at 10:00 a.m. EST at the Boston Marriott Copley Place in Bo...

  11. Show article details.

    Idera to Present at the 2014 RBC Capital Markets’ Global Healthcare Conference

    Business Wire – 4:02 PM ET 02/18/2014

    Idera Pharmaceuticals, Inc. (IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Company management will present at the 2014 RBC Capital Markets’ Global Healthcare Conference on Tuesday, February 25, 2014 at 8:00 a.m. EST at the New York Palace Hotel i...

  12. Show article details.

    Idera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants

    Business Wire – 4:15 PM ET 02/10/2014

    Idera Pharmaceuticals, Inc. (IDRA) today announced the closing of its previously announced underwritten public offering of 7,867,438 shares of common stock at an offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at an offering price of $3.99 per pre-funded warrant, which is the per share public offering price for the common st...

  13. Show article details.

    Idera to Present at 16th Annual BIO CEO & Investor Conference

    Business Wire – 8:30 AM ET 02/06/2014

    Idera Pharmaceuticals, Inc. (IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that Sudhir Agrawal, D.Phil., Chief Executive Officer of Idera, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. A live au...

  14. Show article details.

    Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

    Business Wire – 9:08 AM ET 02/05/2014

    Idera Pharmaceuticals, Inc. (IDRA) today announced the pricing of an underwritten public offering of 6,841,250 shares of common stock for a public offering price of $4.00 per share, and pre-funded warrants to purchase up to an aggregate of 2,158,750 shares of common stock at the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant.

  15. Show article details.

    Idera Pharmaceuticals Announces Public Offering of Common Stock and Pre-Funded Warrants

    Business Wire – 4:01 PM ET 02/04/2014

    Idera Pharmaceuticals, Inc. (IDRA) today announced that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of its common stock in an underwritten public offering.

  16. Show article details.

    Idera Announces Publication of New Data Demonstrating Impact of Inhibiting TLRs 7, 8, and 9 in a Preclinical Model of Autoimmune Disease

    Business Wire – 8:00 AM ET 01/22/2014

    Idera Pharmaceuticals, Inc. (IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced the publication of a study supporting the potential role of the suppression of Toll-like-receptors 7, 8, and 9 in the treatment of psoriasis.

Page:

Today's and Upcoming Events

  • May
    15

    IDRA to announce Q1 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • Mar
    13

    IDRA Earnings Conference Call at 8:30 AM Listen

Data provided by Wall Street Horizon, Inc. © 2014

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.